Response to Office Action of October 30, 2007 And Response to Non-compliant Amendment of May 21, 2008 Serial No. 10/637,159 Attorney Docket No. 065382-0006 Electronically filed May 29, 2008

LISTING OF THE CLAIMS

1. (Currently amended). A method of increasing the production of a biologically active compound in a <u>Saccharopolyspora</u>, <u>Aeromicrobium or Streptomyces</u> cell wherein the biologically active compound is derived—at least in part-from methylmalonyl-CoA, the method comprising the step of inhibiting [[the]] <u>an</u> activity of methylmalonyl-CoA mutase;

wherein the biologically active compound is selected from the group consisting of an immunosuppressant, an anti-fungal agent, and anti-parasitic agent, an antibiotic, and an animal feed promotant; and

wherein the production of the biologically active compound is increased when compared to production of the same biologically active compound from the cell wherein the activity of methylmalonyl-CoA mutase is not inhibited.

- 2. (Withdrawn). The method of claim 1 wherein the biologically active compound is an immunosuppressant.
- 3. (Withdrawn). The method of claim 2 wherein the immunosuppessant is rapamycin, FK520, or ascomycin.
- 4. (Withdrawn). The method of claim 1 wherein the biologically active compound is an antifungal agent.
- 5. (Withdrawn). The method of claim 4 wherein the antifungal agent is rapamycin, candicidin or soraphen.
- 6. (Withdrawn). The method of claim 1 wherein the biologically active compound is an antiparasitic agent.
 - 7. (Withdrawn). The method of claim 6 wherein the antiparasitic agent is avermectin.
 - 8. (Original). The method of claim 1 wherein the biologically active compound is an antibiotic.
 - 9. (Original). The method of claim 8 wherein the antibiotic is a polyketide antibiotic.

Response to Office Action of October 30, 2007 And Response to Non-compliant Amendment of May 21, 2008 Serial No. 10/637,159 Attorney Docket No. 065382-0006 Electronically filed May 29, 2008

- 10. (Original). The method of claim 9 wherein the polyketide antibiotic is a macrolide polyketide antibiotic.
- 11. (Original). The method of claim 10 wherein the macrolide polyketide antibiotic is erythromycin, tylosin, niddamycin, spiramycin, oleandomycin, methymycin, neomethymycin, narbomycin, pikromycin, or lankamycin.
- 12. (Withdrawn). The method of claim 1 wherein the biologically active compound is an animal feed promotant.
 - 13. (Withdrawn). The method of claim 12 wherein the animal feed promotant is a monensin.
 - 14. (Withdrawn). The method of claim 12 wherein the monensin is monensin A or monensin B.
 - 15.-17. (Canceled).
- 18. (Original). The method of claim 17 wherein the bacterial cell is a *Saccharopolyspora* erythraea or an *Aeromicrobium* erythreum.
- 19. (Original). The method of claim 18 wherein the bacterial cell is *Streptomyces* fradiae, *Streptomyces* avermitilis, *Streptomyces cinnamonensis*, *Streptomyces* antibioticus, *Streptomyces* venezuelae, *Streptomyces* violaceoniger, *Streptomyces* hygroscopicus, *Streptomyces* spp. FR-008, or *Streptomyces* griseus.
 - 20.-23. (Cancelled)
- 24. (Original). The method of claim 1 wherein inhibiting is accomplished by reducing the level of a co-factor necessary for methylmalonyl-CoA mutase activity.
 - 25. (Original). The method of claim 24 wherein the co-factor is coenzyme B12.
- 26. (Currently amended). The method of claim 25 wherein the level of coenzyme B12 is reduced by inhibiting the transcription of a [[ωb]] cob(Dalamin adenosyltransferase gene.

Response to Office Action of October 30, 2007 And Response to Non-compliant Amendment of May 21, 2008 Serial No. 10/637,159 Attorney Docket No. 065382-0006 Electronically filed May 29, 2008

- 27. (Withdrawn). The method of claim 1 wherein inhibiting the activity of methylmalonyl-CoA mutase is accomplished by inhibiting the transcription of a gene for methylmalonyl-CoA mutase.
- 28. (Withdrawn). The method of claim 27 wherein inhibiting the transcription of a gene for methylmalonyl-CoA mutase is accomplished by mutating the gene for methylmalonyl-CoA mutase such that the mutated gene does not encode an enzymatically active methylmalonyl-CoA mutase.
- 29. (Withdrawn). The method of claim 28 wherein mutating is accomplished by mutating a wild type methylmalonyl CoA gene in vitro.
- 30. (Withdrawn). A method of increasing the production of an antibiotic in a bacterial cell wherein the antibiotic is derived at least in part from methylmalonyl-CoA, the method comprising the step of inhibiting the activity of methylmalonyl-CoA mutase in the bacterial cell.
 - 31. (Withdrawn). The method of claim 30 wherein the antibiotic is a polyketide macrolide antibiotic.
- 32. (Withdrawn). The method of claim 31 wherein the polyketide macrolide antibiotic is erythromycin.
- 33. (Withdrawn). The method of claim 32 wherein the bacterial cell is a *Saccharopolyspora* or *Aeromicrobium*.
- 34. (Withdrawn). The method of claim 33 wherein the bacterial cell is *Saccharopolyspora* erythraea or *Aeromicrobium* erythreum.